Literature DB >> 18036421

An assessment of the onset and duration of action of olopatadine nasal spray.

Piyush Patel1, Peter S Roland, Bradley F Marple, Paul J Benninger, Harriet Margalias, Michael Brubaker, Sally F Beezley, Susan F Beezley, Margaret Drake, Susan L Potts, G Michael Wall.   

Abstract

OBJECTIVE: Seasonal allergic rhinitis (SAR) is a highly prevalent disease. This study was conducted to evaluate the onset and duration of action of three concentrations of olopatadine nasal spray.
METHODS: This was a randomized, double-blind, single-dose, placebo-controlled study, conducted in an environmental exposure chamber in patients with SAR. A total of 320 patients were exposed to ragweed allergen in the chamber and randomized to olopatadine nasal spray 0.2%, 0.4%, 0.6%, or placebo nasal spray. Symptoms (sneezing, runny, itchy, and stuffy nose) were self-assessed during a 12-hour study period.
RESULTS: All concentrations of olopatadine nasal spray provided clinically meaningful reductions in total nasal symptom scores at 30 minutes compared to the placebo. Olopatadine nasal spray 0.6% was significantly more effective (P < 0.05) than placebo nasal spray at all time-points starting at 90 minutes post-dose and continuing over 12 hours.
CONCLUSIONS: Olopatadine nasal spray 0.6% demonstrated a fast onset of action and maintained an effect for at least 12 hours after dosing.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18036421     DOI: 10.1016/j.otohns.2007.08.005

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  7 in total

Review 1.  ARIA 2019, Allerjik Rinite Tedavi Yaklaşımı-Türkiye.

Authors:  Ayşe Arzu Yorgancıoğlu; Bilun Gemicioğlu; Cemal Cingi; Ömer Kalaycı; Ali Fuat Kalyoncu; Claus Bachert; Peter Hellings; Oliver Pfaar; Holger J Schünemann; Dana Wallace; Anna Bedbrook; Wienczyslawa Czarlewski; Jean Bousquet
Journal:  Turk Thorac J       Date:  2020-03-01

Review 2.  Allergic conjunctivitis and the impact of allergic rhinitis.

Authors:  Leonard Bielory
Journal:  Curr Allergy Asthma Rep       Date:  2010-03       Impact factor: 4.806

Review 3.  Controlled Allergen Challenge Facilities and Their Unique Contributions to Allergic Rhinitis Research.

Authors:  Michelle L North; Mena Soliman; Terry Walker; Lisa M Steacy; Anne K Ellis
Journal:  Curr Allergy Asthma Rep       Date:  2015-04       Impact factor: 4.806

Review 4.  ARIA 2019 Care Pathways for Allergic Rhinitis in the Kuwait Health Care System.

Authors:  Mona Al-Ahmad; Jasmina Nurkic; Claus Bachert; Oliver Pfaar; Holger J Schunemann; Wienczyslawa Czarlewski; Anna Bedbrook; Jean Bosquet
Journal:  Med Princ Pract       Date:  2020-10-23       Impact factor: 1.927

Review 5.  Ragweed-induced allergic rhinoconjunctivitis: current and emerging treatment options.

Authors:  Friedrich Ihler; Martin Canis
Journal:  J Asthma Allergy       Date:  2015-02-16

Review 6.  Rapid onset of action and reduced nasal hyperreactivity: new targets in allergic rhinitis management.

Authors:  C Bachert; J Bousquet; P Hellings
Journal:  Clin Transl Allergy       Date:  2018-06-25       Impact factor: 5.871

Review 7.  The Nose as a Route for Therapy: Part 1. Pharmacotherapy.

Authors:  Cemal Cingi; Nuray Bayar Muluk; Dimitrios I Mitsias; Nikolaos G Papadopoulos; Ludger Klimek; Anu Laulajainen-Hongisto; Maija Hytönen; Sanna Katriina Toppila-Salmi; Glenis Kathleen Scadding
Journal:  Front Allergy       Date:  2021-02-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.